Dr. Yancey Gillespie obtained B.A. (Biology & Chemistry), M.Sc. (Cytogenetics) and Ph.D. (Immunology & Immunogenetics) degrees at the University of Mississippi, finishing in 1971. Following a NCI F31 postdoctoral fellowship at the University of Kansas Medical Center, he was appointed to the Department of Pathology as Instructor. In 1975, he joined Scripps Clinic and Research Foundation in La Jolla. In 1977, he moved as Assistant Professor of Pathology to the University of North Carolina-Chapel Hill. In 1979, he transferred to the Department of Surgery, Division of Neurosurgery to direct the Brain Tumor Immunology research program. In 1986, Dr. Gillespie came to UAB as tenured Associate Professor of Surgery to direct brain tumor research efforts in the Division of Neurosurgery. He is currently Professor of Surgery with secondary appointments in the Departments of Microbiology and Cell Biology. Dr. Gillespie is Director of the UAB Brain Tumor Specialized Program Of Research Excellence (SPORE) and Co-Leader of the Neuro-Oncology Program in the Comprehensive Cancer Center. He directs both the Brain Tumor Tissue Core and the Brain Tumor Animal Models Core facilities.
Research Interests: Molecular and Viral Therapy of Malignant Primary Brain Tumors
Publications
Featured Publications:
Radbill AE, Reddy AT, Markert JM, Wyss JM, Pike MM, Akella NS, Bharara N, Gillespie GY. Effects of G207, a conditionally replication-competent oncolytic herpes simplex virus, on the developing mammalian brain. J Neurovirol. 2007 Apr;13(2):118-29. PMID: 17505980
Shah AC, Parker JN, Gillespie GY, Lakeman FD, Meleth S, Markert JM, Cassady KA. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses. Gene Ther. 2007 Jul;14(13):1045-54. Epub 2007 Apr 12. PMID: 17429445
Markert JM, Liechty PG, Wang W, Gaston S, Braz E, Karrasch M, Nabors LB, Markiewicz M, Lakeman AD, Palmer CA, Parker JN, Whitley RJ, Gillespie GY. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther. 2009 Jan;17(1):199-207. Epub 2008 Oct 28. PMID: 18957964
Oliva CR, Nozell SE, Diers A, McClugage SG 3rd, Sarkaria JN, Markert JM, Darley-Usmar VM, Bailey SM, Gillespie GY, Landar A, Griguer CE. Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain. J Biol Chem. 2010 Dec 17;285(51):39759-67. Epub 2010 Sep 24. PMID: 20870728
Friedman GK, Gillespie GY. Cancer Stem Cells and Pediatric Solid Tumors. Cancers (Basel). 2011 Jan 14;3(1):298-318. PMID: 21394230
Advani SJ, Markert JM, Sood RF, Samuel S, Gillespie GY, Shao MY, Roizman B, Weichselbaum RR. Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1. Gene Ther. 2011 Nov;18(11):1098-102. doi: 10.1038/gt.2011.61. Epub 2011 May 5. PMID: 21544094
Oliva CR, Moellering DR, Gillespie GY, Griguer CE Acquisition of chemoresistance in gliomas is associated with increased mitochondrial coupling and decreased ROS production. PLoS One. 2011;6(9):e24665. Epub 2011 Sep 9.PMID: 21931801
McFarland BC, Ma JY, Langford CP, Gillespie GY, Yu H, Zheng Y, Nozell SE, Huszar D, Benveniste EN. Therapeutic Potential of AZD1480 for the Treatment of Human Glioblastoma. Mol Cancer Ther. 2011 Oct 25. [Epub ahead of print] PMID: 22027691